Patents by Inventor Steven H. Selman
Steven H. Selman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8211858Abstract: The present invention relates to a modified plasminogen activator inhibitor type-1 (PAI-1) molecule that displays an increased in vivo half-life of the active form of PAI-1, but is deficient in one or more functional activities as compared to the wild-type PAI-1 protein. The modified PAI-1 molecule that displays an increased half-life further displays at least one of the following functional characteristics: (i) decreased binding activity to at least one of the following molecules: urokinase plasminogen activator (uPA), tissue plasminogen activator (tPA) and vitronectin (Vn); and (ii) decreased specific activity against at least one of the following molecules: uPA, tPA and Vn. The invention further relates to pharmaceutical compositions comprising modified PAI-1 molecules and methods of using these pharmaceutical compositions for treatment.Type: GrantFiled: April 24, 2008Date of Patent: July 3, 2012Assignee: The University of ToledoInventors: Jerzy Jankun, Ewa Skrzypczak-Jankun, Steven H. Selman
-
Patent number: 8133491Abstract: A method for treating a subject includes injecting a therapeutic amount of a composition derived from a cobra toxin into a tissue of the subject in an amount sufficient to diminish at least one symptom of a hyperplastic disorder.Type: GrantFiled: January 29, 2010Date of Patent: March 13, 2012Assignee: The University of ToledoInventors: Steven H. Selman, Channing L. Hinman
-
Publication number: 20100184667Abstract: The present invention relates to a modified plasminogen activator inhibitor type-1 (PAI-1) molecule that displays CN an increased in vivo half-life of the active form of PAI-1, but is deficient in one or more functional activities as compared to the wild-type PAI-1 protein. The modified PAI-1 molecule that displays an increased half-life further displays at least one of the following funtional characteristics: (i) decreased binding activity to at least one of the following molecules: urokinase plasminogen activator (uPA), tissue plasminogen activator (tPA) and vitronectin (Vn); and (ii) decreased specific activity against at least one of the following molecules: uPA, tPA and Vn. The invention further relates to pharmaceutical compositions comprising modified PAI-1 molecules and methods of using these pharmaceutical compositions for treatment.Type: ApplicationFiled: April 24, 2008Publication date: July 22, 2010Applicant: THE UNIVERSITY OF TOLEDOInventors: Jerzy Jankun, Ewa Skrzypczak-Jankun, Steven H. Selman
-
Publication number: 20100137209Abstract: The present invention is based upon the discovery that modified plasminogen activator inhibitor type-I (PAI-1) in which two or more amino acid residues that do not contain a sulfhydryl group have been replaced with amino acid residues that contain a sulfhydryl group and, therefore, forms intramolecular disulfide bonds, have increased in vivo half-life. Also disclosed are the modified PAI-1 proteins, derivatives and analogs thereof, specific antibodies, nucleic acid molecules and host cells. Methods for producing modified PAI-1, derivatives and analogs are also provided. The invention further relates to Therapeutics, pharmaceutical compositions and method of using the composition for treatment. The invention may be used to inhibit angiogenesis in a subject, thereby treating diseases or conditions associated with undesired angiogenesis and cell proliferation. Such conditions include psoriasis, chronic inflammation, tumor invasion and metastasis and conditions in which angiogenesis is pathogenic.Type: ApplicationFiled: September 18, 2009Publication date: June 3, 2010Inventors: Rafal Swiercz, Steven H. Selman, Jerzy Jankun, Joanna Chorostowska-Wynimko, Ewa Skrzypczak-Jankun
-
Patent number: 7592422Abstract: The present invention is based upon the discovery that modified plasminogen activator inhibitor type-I (PAI-1) in which two or more amino acid residues that do not contain a sulfhydryl group have been replaced with amino acid residues that contain a sulfhydryl group and, therefore, forms intramolecular disulfide bonds, have increased in vivo half-life. Also disclosed are the modified PAI-1 proteins, derivatives and analogs thereof, specific antibodies, nucleic acid molecules and host cells. Methods for producing modified PAI-1, derivatives and analogs are also provided. The invention further relates to Therapeutics, pharmaceutical compositions and method of using the composition for treatment. The invention may be used to inhibit angiogenesis in a subject, thereby treating diseases or conditions associated with undesired angiogenesis and cell proliferation. Such conditions include psoriasis, chronic inflammation, tumor invasion and metastasis and conditions in which angiogenesis is pathogenic.Type: GrantFiled: March 4, 2003Date of Patent: September 22, 2009Assignee: Medical College of OhioInventors: Rafal Swiercz, Steven H. Selman, Jerzy Jankun, Joanna Chorostowska-Wynimko, Ewa Skrzypczak-Jankun
-
Publication number: 20090227669Abstract: Polyphenol- and especially catechin-containing compositions (e.g., Polyphenon E) are instilled in the bladder of a subject that previously underwent surgical resection or removal of bladder cancer to reduce cancer growth and/or recurrence.Type: ApplicationFiled: April 14, 2009Publication date: September 10, 2009Applicant: THE UNIVERSITY OF TOLEDOInventors: J. Karl Kemberling, Steven H. Selman
-
Publication number: 20020193850Abstract: The present invention provides a method for diagnosing or treating prostatic tissue in a human or animal patient which comprises sensitizing the prostatic tissue with an effective amount of a photosensitive composition which accumulates in the prostatic tissue and exposing the sensitized tissue to a source of light energy for a predetermined time and intensity sufficient to cause cellular and/or tissue function of the sensitized prostatic tissue to diminish or cease.Type: ApplicationFiled: July 22, 2002Publication date: December 19, 2002Inventor: Steven H. Selman
-
Patent number: 6025351Abstract: Families of Diels Alder adducts and of metal complexes of Diels Alder adducts, which are useful as particularly active compounds for use in photodynamic therapy, are disclosed. The Diels Alder adducts and a preferred family of metal complexes have the structures of Formulas 3 and 4, below: ##STR1## where R1, R2, R3 and R4 can be the same or different, and each is methyl, ethyl, an amino acid moiety which is a part of an amide produced by reaction between an amine function of a naturally occurring amino acid and a carbonyl function of the adduct, or a monoclonal antibody moiety which is attached to the adduct moiety through a carbonyl which is a part of an amide produced by reaction between an amine function of a monoclonal antibody and a CO.sub.2 R', CH.sub.2 CO.sub.2 R' or CH.sub.2 CH.sub.2 CO.sub.Type: GrantFiled: November 26, 1997Date of Patent: February 15, 2000Assignees: University of Toledo, Medical College of OhioInventors: Alan R. Morgan, Steven H. Selman
-
Patent number: 6011563Abstract: A system and method is provided for optimizing a laser light fractionation during photodynamic therapy of a tumor. The tumor is destroyed through the production of singlet oxygen and successful photodynamic therapy treatment requires the maintenance of tumor oxygen above a specified critical level. Depending on the tumor, the photosensitizer concentration, and the laser fluence, sustained irradiation of the tumor will deplete the oxygen below the critical level. When the laser is turned off, oxygen diffuses into the tumor to provide sustained levels of singlet oxygen. The control system controls the operation cycle of the laser and the various surgical parameters. Data regarding the sensitizer, the laser characteristics, and the oxygen features of the tumor are input into the control system for simulation of the PDT treatment. As part of the simulation, the optimal fractionation cycle for the laser is predicted. The data may be adjusted for conducting additional simulations.Type: GrantFiled: April 24, 1995Date of Patent: January 4, 2000Assignee: The University of ToledoInventors: Ronald L. Fournier, Jeffrey Henning, James A. Hampton, Steven H. Selman
-
Patent number: 5744598Abstract: Purified imines of porphyrins, chlorins, bateriochlorins, chlorophylls, bacteriochlorophylls, purpurins, reduced purpurins, verdins, Diels Alder adducts, benzochlorins and metal complexes of the foregoing imines are disclosed. The formulas of the benzochlorinimines and of the benzochlorinimine metal complexes are set forth below: ##STR1## In specific examples, M in the metal complexes is a copper cation that is complexed with two of the nitrogens of the benzochlorinimine R' and R"" are methyl, and R1 through R8 are ethyl.Type: GrantFiled: April 29, 1996Date of Patent: April 28, 1998Assignees: University of Toledo, Medical College of OhioInventors: Dimitris Skalkos, Steven H. Selman, James A. Hampton, Alan R. Morgan
-
Patent number: 5693632Abstract: Families of Diels Alder adducts and of metal complexes of Diels Alder adducts, which are useful as particularly active compounds for use in photodynamic therapy, are disclosed. The Diels Alder adducts and a preferred family of metal complexes have the structures of Formulas 1, 2, 3 and 4, below: ##STR1## where R1, R2, R3 and R4 can be the same or different, and each is methyl, ethyl or an amino acid moiety which is a part of an amide produced by reaction between an amine function of a naturally occurring amino acid and a carbonyl function of the adduct, R5, R6 and R7 can be the same or different, and each is ethyl or an amino acid moiety which is a part of an amide produced by reaction between an amine function of a naturally occurring amino acid and a carbonyl function of the adduct, M comprises metal cation.Type: GrantFiled: November 6, 1996Date of Patent: December 2, 1997Assignees: The University of Toledo, The Medical College of OhioInventors: Alan R. Morgan, Steven H. Selman
-
Patent number: 5587394Abstract: Families of Diels Alder adducts and of metal complexes of Diels Alder adducts, which are useful as particularly active compounds for use in photodynamic therapy, are disclosed. The Diels Alder adducts and a preferred family of metal complexes have the structures of Formulas 1, 2, 3 and 4, below: ##STR1## where R1, R2, R3 and R4 can be the same or different, and each is methyl, ethyl or an amino acid moiety which is a part of an amide produced by reaction between an amine function of a naturally occurring amino acid and a carbonyl function of the adduct, R5, R6 and R7 can be the same or different, and each is ethyl or an amino acid moiety which is a part of an amide produced by reaction between an amine function of a naturally occurring amino acid and a carbonyl function of the adduct.Type: GrantFiled: June 7, 1995Date of Patent: December 24, 1996Assignees: The University of Toledo, Medical College of OhioInventors: Alan R. Morgan, Steven H. Selman
-
Patent number: 5563262Abstract: Families of Diels Alder adducts and of metal complexes of Diels Alder adducts, which are useful as particularly active compounds for use in photodynamic therapy, are disclosed. The Diels Alder adducts and a preferred family of metal complexes have the structures of Formulas 1, 2, 3 and 4, below: ##STR1## where R1, R2, R3 and R4 can be the same or different, and each is methyl, ethyl or an amino acid moiety which is a part of an amide produced by reaction between an amine function of a naturally occurring amino acid and a carbonyl function of the adduct, R5, R6 and R7 can be the same or different, and each is ethyl or an amino acid moiety which is a part of an amide produced by reaction between an amine function of a naturally occurring amino acid and a carbonyl function of the adduct, M comprises a metal cation, e.g., Sn or Zn, that is complexed with two of the nitrogens of the adduct, and R8 is an alkyl group other than t-butyl having from one to four carbon atoms.Type: GrantFiled: October 11, 1994Date of Patent: October 8, 1996Assignees: University of Toledo, Medical College of OhioInventors: Alan R. Morgan, Steven H. Selman
-
Patent number: 5552134Abstract: A family of benzochlorins, a family of verdins, a family of porphyrin derivatives and metal complexes thereof are disclosed. The benzochlorins have the formula of FIG. 3 of the attached drawings; their metal complexes have the formula of FIG. 1. The verdins have the formula of FIG. 4 of the attached drawings; their metal complexes have the formula of FIG. 2. The porphyrin derivatives have the formula of FIG. 7 of the attached drawings; their metal complexes have the formula of FIG. 8. Solutions of the benzochlorins, verdins, porphyrin derivatives and metal complexes which are physiologically acceptable for intravenous administration are also disclosed, as are emulsions or suspensions of the solutions, and compositions which additionally include cyclodextrin, and wherein the molecules of the benzochlorin, verdin, porphyrin derivative or metal complex are encapsulated within the molecules of the cyclodextrin. The solvent for the solutions can be a product of the reaction of ethylene oxide with castor oil.Type: GrantFiled: June 7, 1995Date of Patent: September 3, 1996Assignees: University of Toledo, Medical College of OhioInventors: Alan R. Morgan, Steven H. Selman
-
Patent number: 5534506Abstract: The treatment of blood and other body fluids and tissues, the detection of tumors and the treatment of patients is disclosed. The treatment and detection involve the use of families of chlorins, families of purpurins and families of metal complexes of chlorins and purpurins. The purpurins and their metal complexes have the structures of FIGS. 1 , 7, 14-18, 29-38, 44-48 and 54-58 of the attached drawings. The chlorins and their metal complexes have the formulas of FIGS. 2 , 8, 19, 20, 22, 23, 24, 25, 27, 28, 39, 40, 42, 43 and 49-53 of the attached drawings. Solutions of the purpurins, of the foregoing and other chlorins and of the metal complexes which are physiologically acceptable for intravenous administration are also disclosed, as are emulsions or suspensions of the solutions. The solvent for the solutions can be a product of the reaction of ethylene oxide with castor oil.Type: GrantFiled: June 20, 1994Date of Patent: July 9, 1996Assignees: University of Toledo, Medical College of Ohio, St. Vincent Medical CenterInventors: Alan R. Morgan, Steven H. Selman, Martha Kreimer-Birnbaum
-
Patent number: 5514669Abstract: The present invention provides a method for diagnosing or treating prostatic tissue in a human or animal patient which comprises sensitizing the prostatic tissue with an effective amount of a photosensitive composition which accumulates in the prostatic tissue and exposing the sensitized tissue to a source of light energy for a predetermined time and intensity sufficient to cause cellular and/or tissue function of the sensitized prostatic tissue to diminish or cease.Type: GrantFiled: September 29, 1993Date of Patent: May 7, 1996Assignee: Medical College of OhioInventor: Steven H. Selman
-
Patent number: 5512559Abstract: Purified imines of porphyrins, chlorins, bateriochlorins, chlorophylls, bacteriochlorophylls, purpurins, reduced purpurins, verdins, Diels Alder adducts, benzochlorins and metal complexes of the foregoing imines are disclosed. The formulas of the benzochlorinimines and of the benzochlorinimine metal complexes are set forth below: ##STR1## In specific examples, M in the metal complexes is a copper cation that is complexed with two of the nitrogens of the benzochlorinimine R' and R"" are methyl, and R1 through R8 are ethyl.Type: GrantFiled: January 19, 1995Date of Patent: April 30, 1996Assignee: The University of Toledo and Medical College of OhioInventors: Dimitris Skalkos, Steven H. Selman, James A. Hampton
-
Patent number: 5438051Abstract: A family of benzochlorins, a family of verdins, a family of porphyrin derivatives and metal complexes thereof are disclosed. The benzochlorins have the formula of FIG. 3 of the attached drawings; their metal complexes have the formula of FIG. 1 . The verdins have the formula of FIG. 4 of the attached drawings; their metal complexes have the formula of FIG. 2. The porphyrin derivatives have the formula of FIG. 7 of the attached drawings; their metal complexes have the formula of FIG. 8. Solutions of the benzochlorins, verdins, porphyrin derivatives and metal complexes which are physiologically acceptable for intravenous administration are also disclosed, as are emulsions or suspensions of the solutions, and compositions which additionally include cyclodextrin, and wherein the molecules of the benzochlorin, verdin, porphyrin derivative or metal complex are encapsulated within the molecules of the cyclodextrin. The solvent for the solutions can be a product of the reaction of ethylene oxide with castor oil.Type: GrantFiled: October 4, 1993Date of Patent: August 1, 1995Assignees: University of Toledo, Medical College of OhioInventors: Alan R. Morgan, Steven H. Selman
-
Patent number: 5424305Abstract: Purified imines of porphyrins, chlorins, bateriochlorins, chlorophylls, bacteriochlorophylls, purpurins, reduced purpurins, verdins, Diels Alder adducts, benzochlorins and metal complexes of the foregoing imines are disclosed for retarding growth of cancer tumors such as bladder tumors. The formulas of the benzochlorinimines and of the benzochlorinimine metal complexes are set forth below: ##STR1## In specific examples, M in the metal complexes is a copper cation that is complexed with two of the nitrogens of the benzochlorinimine R' and R"" are methyl, and R1 through R8 are ethyl.Type: GrantFiled: November 24, 1993Date of Patent: June 13, 1995Assignees: The University of Toledo, Medical College of OhioInventors: Dimitris Skalkos, Steven H. Selman, James A. Hampton
-
Patent number: 5405369Abstract: The present invention provides a method for treating a human or animal patient amenable an organ augmentation with gastro-intestinal tissue which is, or will be surgically transplanted into the patient's organ. The gastro-intestinal tissue is sensitized with an effective amount of a photosensitive composition which accumulates in the gastro-intestinal tissue. The sensitized tissue is exposed to a source of electromagnetic radiation energy for a predetermined time, wavelength and intensity sufficient to cause cellular and/or mucosal tissue function of the sensitized tissue to diminish or cease.Type: GrantFiled: January 25, 1994Date of Patent: April 11, 1995Assignee: Medical College of OhioInventors: Steven H. Selman, Kenneth A. Kropp, Gregory D. Haselhuhn